Foundation Medicine said this week that it is working with Array BioPharma to help identify cancer patients who will respond to targeted therapy with Array's cancer agents.
Under the collaboration, Foundation Medicine will use its DNA sequencing and analysis capabilities to determine the genetic profile of tumors from patients who are treated with Array's drugs.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
